Pharmacoeconomics and Duromine

Pharmacoeconomics is a new science, which studies clinical and economic benefits of medications and the schemes of drug therapy.

When assessing the economic aspects of the use of Duromine weight loss drug, we must take into account any direct and indirect costs that are associated with it.

The prices of Duromine anti-obesity drug and the amount of indirect costs mostly depend on the therapy duration and obesity degree (i.e. on disability of patients and disease severity).

It is noteworthy that the direct costs on Duromine treatment are just a small part of all costs, borne by society because of overweight patients.

Recently, the economic costs on regular medical help for patients that use Duromine anorectic drug in hospitals and that are incapable of work, have increased significantly.

In the treatment of overweight patients, the most expensive treatment is considered the one that involves a stationary treatment by means of Duromine slimming medication. Such stationary treatment can be even pricier when a patient suffers from obesity and other comorbidities at the same time.

For instance, such comorbidities are arrhythmia, glaucoma, hypothyroidism, progressing atherosclerosis, pulmonary hypertension, developmental abnormalities of the heart valves and cerebrovascular insufficiency.

When using Duromine, the listed diseases require a special care. Because the effect of Duromine psychostimulant on the patient’s body can worsen the overall health.

Above all, the price of Duromine consists of the costs on side effects treatment and a clinical efficiency of Duromine drug. Usually, side effects are mild or temporary.

In rare cases, when using Duromine, side effects can be more pronounced and require a certain medical treatment. In turn, extra medical services can increase the costs on the treatment with Duromine anorectic drug.

The volume of direct and indirect costs on Duromine use is proportional to the frequency of relapses and severity of irreversible symptoms of diseases.

The indirect costs involve the reduced standard of living of obese patients and their family members. The cost of Duromine treatment has its peculiarities, unlike other methods of anti-obesity therapy.

The peculiarities of Duromine treatment are the high medical costs on the diagnosis, treatment and prophylaxis of obesity.

Scientists found out that overweight treatment by means of Duromine anorectic drug at home, compared to the treatment in the hospital reduces the economic burden on the healthcare system and improves the standard of living of both a patient himself and his family.

The analysis of an average price of Duromine anorectic drug, including nonmedical and indirect costs, has revealed the fact that Duromine price is increased along the growth of obesity degree, which affects the duration of hospitalization of a patient.